Purple Biotech Ltd. (PPBT)
NASDAQ: PPBT · IEX Real-Time Price · USD
-0.001 (-0.11%)
At close: Apr 12, 2024, 3:58 PM
-0.002 (-0.34%)
After-hours: Apr 12, 2024, 6:02 PM EDT

Company Description

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.

Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.

The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.

The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020.

The company is headquartered in Rehovot, Israel.

Purple Biotech Ltd.
Purple Biotech logo
Country Israel
Founded 2010
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Gil Efron CPA, M.A.

Contact Details

4 Oppenheimer Street, Science Park
Rehovot, L3 7670104
Phone 97239333121
Website purple-biotech.com

Stock Details

Ticker Symbol PPBT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001614744
CUSIP Number 74638P109
ISIN Number US74638P1093
SIC Code 2834

Key Executives

Name Position
Gil Efron CPA, M.A. Chief Executive Officer
Dr. Michael Schickler Ph.D. Head of Clinical and Regulatory Affairs
Lior Fhima CPA, M.B.A. Chief Financial Officer
Ido Morpurgo B.Sc., L.L.M. Vice President of Operations

Latest SEC Filings

Date Type Title
Apr 2, 2024 EFFECT Notice of Effectiveness
Mar 28, 2024 POS AM Post-Effective amendments for registration statement
Mar 28, 2024 6-K Report of foreign issuer
Mar 14, 2024 6-K Report of foreign issuer
Mar 6, 2024 6-K Report of foreign issuer
Mar 5, 2024 20-F Annual and transition report of foreign private issuers
Mar 5, 2024 6-K Report of foreign issuer
Feb 27, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 6-K Report of foreign issuer